



Mvasi[®] (bevacizumab-awwb) – Updated indication and boxed warning removal

- On June 24, 2019, the [FDA approved](#) Amgen's [Mvasi \(bevacizumab-awwb\)](#), for recurrent glioblastoma in adults.
 - Previously, the indication was glioblastoma, as a single agent for adult patients with progressive disease following prior therapy.
 - The updated indication is the same as the reference product, Genentech's [Avastin \(bevacizumab\)](#).
- Mvasi and Avastin are also indicated for metastatic colorectal cancer; non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; and persistent, recurrent, or metastatic carcinoma of the cervix.
- Avastin carries an additional indication for epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- In addition, the *boxed warning* for gastrointestinal perforations, surgery and wound healing complications, and hemorrhage was removed from the Mvasi label.
 - The *boxed warning* was also removed from the Avastin drug label on June 20, 2019.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.